Evidence map›Paper›PMID 25965345›Full record

ArticlePloS one2015

Optimization of Invasion-Specific Effects of Betulin Derivatives on Prostate Cancer Cells through Lead Development.

Ville Härmä, Raisa Haavikko, Johannes Virtanen, Ilmari Ahonen, Hannu-Pekka Schukov, Sami Alakurtti, Enkhee Purev, Heiko Rischer, Jari Yli-Kauhaluoma, Vânia M Moreira and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. International journal of molecular sciences · 2019
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Ville HärmäIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Turku, Finland.
Raisa HaavikkoDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Johannes VirtanenIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Turku, Finland.
Ilmari AhonenTurku Centre for Biotechnology BTK, University of Turku, Turku, Finland.
Hannu-Pekka SchukovUniversity of Turku, Faculty of Medicine, Institute of Biomedicine, Turku, Finland.
Sami AlakurttiProcess Chemistry and Environmental Engineering, VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Enkhee PurevIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Turku, Finland; National University of Mongolia, Ulanbataar, Mongolia.
Heiko RischerIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Jari Yli-KauhaluomaDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Vânia M MoreiraDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Matthias NeesIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Turku, Finland; Turku Centre for Biotechnology BTK, University of Turku, Turku, Finland.
Kirsi-Marja Oksman-CaldenteyIndustrial Biotechnology, VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
VTT Technical Research Centre of Finland · FIUniversity of Helsinki · FIUniversity of Turku · FINational University of Mongolia · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-invasive and anti-proliferative effects of betulins and abietane derivatives was systematically tested using an organotypic model system of advanced, castration-resistant prostate cancers. A preliminary screen of the initial set of 93 compounds was performed in two-dimensional (2D) growth conditions using non-transformed prostate epithelial cells (EP156T), an androgen-sensitive prostate cancer cell line (LNCaP), and the castration-resistant, highly invasive cell line PC-3. The 25 most promising compounds were all betulin derivatives. These were selected for a focused secondary screen in three-dimensional (3D) growth conditions, with the goal to identify the most effective and specific anti-invasive compounds. Additional sensitivity and cytotoxicity tests were then performed using an extended cell line panel. The effects of these compounds on cell cycle progression, mitosis, proliferation and unspecific cytotoxicity, versus their ability to specifically interfere with cell motility and tumor cell invasion was addressed. To identify potential mechanisms of action and likely compound targets, multiplex profiling of compound effects on a panel of 43 human protein kinases was performed. These target de-convolution studies, combined with the phenotypic analyses of multicellular organoids in 3D models, revealed specific inhibition of AKT signaling linked to effects on the organization of the actin cytoskeleton as the most likely driver of altered cell morphology and motility.

Indexed as

AndrogensBetulinic AcidCell Line, TumorCell ProliferationEpithelial CellsGene Expression Regulation, NeoplasticHumansMaleProstatic Neoplasms, Castration-ResistantProtein KinasesSignal TransductionTriterpenesAndrogensbetulinBetulinic AcidProtein KinasesTriterpenes

Identifiers

PMID25965345
PMCPMC4428838
OpenAlexW274390083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.